Christoph Saal

USPTO Granted Patents = 16 (Patent Applications = 2)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

Years Active: 2011-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10981864 - Crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts (2021-04-20),

2. 10689363 - Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone (2020-06-23),

3. 10577250 - Process for producing of inorganic particulate material (2020-03-03),

4. 10464923 - Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone (2019-11-05),

5. 9517268 - Process for producing inorganic particulate material (2016-12-13),

6. 9308205 - Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyrdazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof (2016-04-12),

7. 9289427 - Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-hydrochloride salt and processes of manufacturing thereof (2016-03-22),

8. 9260393 - Solid state forms of N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide (2016-02-16),

9. 8765684 - Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them (2014-07-01),

10. 8710058 - Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof (2014-04-29),

11. 8586599 - Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof (2013-11-19),

12. 8586545 - Solid materials of {[(2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acid} and methods for obtaining them (2013-11-19),

13. 8383838 - 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 (2013-02-26),

14. 8383679 - Crystal form of calcium 3-acetylaminopropane-1-sulfonate (2013-02-26),

15. 8198452 - Polymorphic forms and process (2012-06-12),

Title: Christoph Saal: Innovator in Pharmaceutical Patents

Introduction

Christoph Saal is a prominent inventor based in Otzberg, Germany, known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has made remarkable advancements in drug formulations and crystalline modifications.

Latest Patents

Saal's latest patents include innovative crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts. These inventions relate to novel crystalline forms and processes for manufacturing pharmaceutical formulations. Additionally, he has developed crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, which are recognized for their utility as BTK inhibitors.

Career Highlights

Throughout his career, Christoph Saal has worked with notable companies such as Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His work in these organizations has contributed to the advancement of pharmaceutical research and development.

Collaborations

Saal has collaborated with esteemed colleagues, including Clemens Kuehn and Axel Becker, to further enhance his research and innovation in the pharmaceutical sector.

Conclusion

Christoph Saal's contributions to pharmaceutical patents and his innovative spirit have made a lasting impact in the industry. His work continues to influence the development of new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.